550 related articles for article (PubMed ID: 21689702)
1. Intestinal lymphatic transport for drug delivery.
Yáñez JA; Wang SW; Knemeyer IW; Wirth MA; Alton KB
Adv Drug Deliv Rev; 2011 Sep; 63(10-11):923-42. PubMed ID: 21689702
[TBL] [Abstract][Full Text] [Related]
2. Lymphatic Drug Absorption via the Enterocytes: Pharmacokinetic Simulation, Modeling, and Considerations for Optimal Drug Development.
Brocks DR; Davies NM
J Pharm Pharm Sci; 2018; 21(1s):254s-270s. PubMed ID: 30348249
[TBL] [Abstract][Full Text] [Related]
3. Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport.
Elz AS; Trevaskis NL; Porter CJH; Bowen JM; Prestidge CA
J Control Release; 2022 Jan; 341():676-701. PubMed ID: 34896450
[TBL] [Abstract][Full Text] [Related]
4. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update.
Trevaskis NL; Charman WN; Porter CJ
Adv Drug Deliv Rev; 2008 Mar; 60(6):702-16. PubMed ID: 18155316
[TBL] [Abstract][Full Text] [Related]
5. Recent approaches of lipid-based delivery system for lymphatic targeting via oral route.
Chaudhary S; Garg T; Murthy RS; Rath G; Goyal AK
J Drug Target; 2014 Dec; 22(10):871-82. PubMed ID: 25148607
[TBL] [Abstract][Full Text] [Related]
6. Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system.
Lee JB; Zgair A; Malec J; Kim TH; Kim MG; Ali J; Qin C; Feng W; Chiang M; Gao X; Voronin G; Garces AE; Lau CL; Chan TH; Hume A; McIntosh TM; Soukarieh F; Al-Hayali M; Cipolla E; Collins HM; Heery DM; Shin BS; Yoo SD; Kagan L; Stocks MJ; Bradshaw TD; Fischer PM; Gershkovich P
J Control Release; 2018 Sep; 286():10-19. PubMed ID: 30016732
[TBL] [Abstract][Full Text] [Related]
7. The role of lymphatic transport in enhancing oral protein and peptide drug delivery.
Wasan KM
Drug Dev Ind Pharm; 2002 Oct; 28(9):1047-58. PubMed ID: 12455465
[TBL] [Abstract][Full Text] [Related]
8. Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability.
Hu L; Quach T; Han S; Lim SF; Yadav P; Senyschyn D; Trevaskis NL; Simpson JS; Porter CJ
Angew Chem Int Ed Engl; 2016 Oct; 55(44):13700-13705. PubMed ID: 27482655
[TBL] [Abstract][Full Text] [Related]
9. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.
Porter CJ; Trevaskis NL; Charman WN
Nat Rev Drug Discov; 2007 Mar; 6(3):231-48. PubMed ID: 17330072
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.
Han S; Quach T; Hu L; Wahab A; Charman WN; Stella VJ; Trevaskis NL; Simpson JS; Porter CJ
J Control Release; 2014 Mar; 177():1-10. PubMed ID: 24398334
[TBL] [Abstract][Full Text] [Related]
11. Intestinal transport as a potential determinant of drug bioavailability.
Nauli AM; Nauli SM
Curr Clin Pharmacol; 2013 Aug; 8(3):247-55. PubMed ID: 23343017
[TBL] [Abstract][Full Text] [Related]
12. The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations.
Franco V; Gershkovich P; Perucca E; Bialer M
Clin Pharmacokinet; 2020 Dec; 59(12):1493-1500. PubMed ID: 32785853
[TBL] [Abstract][Full Text] [Related]
13. Delivery of lipophilic bioactives: assembly, disassembly, and reassembly of lipid nanoparticles.
Yao M; Xiao H; McClements DJ
Annu Rev Food Sci Technol; 2014; 5():53-81. PubMed ID: 24328432
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs.
Dahan A; Hoffman A
Eur J Pharm Sci; 2005 Mar; 24(4):381-8. PubMed ID: 15734305
[TBL] [Abstract][Full Text] [Related]
15. Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs.
Managuli RS; Raut SY; Reddy MS; Mutalik S
Expert Opin Drug Deliv; 2018 Aug; 15(8):787-804. PubMed ID: 30025212
[TBL] [Abstract][Full Text] [Related]
16. Drug delivery to the lymphatic system.
Porter CJ
Crit Rev Ther Drug Carrier Syst; 1997; 14(4):333-93. PubMed ID: 9450175
[TBL] [Abstract][Full Text] [Related]
17. Liposomal delivery systems for intestinal lymphatic drug transport.
Ahn H; Park JH
Biomater Res; 2016; 20():36. PubMed ID: 27895934
[TBL] [Abstract][Full Text] [Related]
18. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.
Khoo SM; Edwards GA; Porter CJ; Charman WN
J Pharm Sci; 2001 Oct; 90(10):1599-607. PubMed ID: 11745718
[TBL] [Abstract][Full Text] [Related]
19. Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism.
Wang X; Zhang C; Han N; Luo J; Zhang S; Wang C; Jia Z; Du S
Drug Deliv; 2021 Dec; 28(1):1664-1672. PubMed ID: 34338567
[TBL] [Abstract][Full Text] [Related]
20. Lipid-based formulations for intestinal lymphatic delivery.
O'Driscoll CM
Eur J Pharm Sci; 2002 Jun; 15(5):405-15. PubMed ID: 12036717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
